Motamed Hajar, Yari Farideh, Javadirad Etrat, Golmohammadi Sima, Alimoradi Saeed, Naleini Ronak, Chegene Lorestani Roya, Nemati Zargaran Fatemeh, Rostamian Mosayeb
Clinical Research Development Center, Imam Reza Hospital Kermanshah University of Medical Sciences Kermanshah Iran.
Clinical Research Development Center, Imam Khomeini and Mohammad Kermanshahi and Farabi and Imam Reza Hospitals Kermanshah University of Medical Sciences Kermanshah Iran.
Health Sci Rep. 2024 Sep 10;7(9):e70061. doi: 10.1002/hsr2.70061. eCollection 2024 Sep.
There are many difficulties in treating , necessitating the creation of more preventative/therapeutic measures like vaccinations. However, after numerous attempts, there is still no authorized and widely accessible vaccine. The present study aimed to systematically review published studies on vaccines in human subjects/samples.
To find published studies, several electronic databases, including Scopus, PubMed, Web of Science, ClinicalKey, ClinicalTrials.gov, and Cochrane Library were searched without time limitation using the appropriate keywords. Studies were scrutinized, and the information from those that met our inclusion criteria was gathered and analyzed.
In total, 691 studies were found, of which 14 articles were included for systematic review. Bacterial lysate containing was the most studied vaccine candidate. As the main indicator of human immune responses to , antibody responses were determined by most studies. The antigen amount, the route of immunization, and the immunization schedule were varying in the studies and were chosen based on several factors such as the disease model, the vaccine type, the vaccination setting (prophylactic or therapeutic), and so on.
The majority of studies asserted that their vaccination was efficient and safe, which was demonstrated by a decrease in the rate of infections and the induction of protective antibody, cell-dependent, and/or cytokine responses. Altogether, the information provided here will help researchers examine the vaccine candidates more closely and take future actions that will be more consistently successful.
治疗存在诸多困难，这就需要研发更多诸如疫苗接种之类的预防/治疗措施。然而，经过多次尝试，仍没有获得授权且广泛可用的疫苗。本研究旨在系统回顾已发表的关于人体受试者/样本中[某种疾病名称]疫苗的研究。
为查找已发表的研究，使用适当关键词对包括Scopus、PubMed、科学网、ClinicalKey、ClinicalTrials.gov和Cochrane图书馆在内的多个电子数据库进行了无时间限制的检索。对研究进行了仔细审查，并收集和分析了符合我们纳入标准的研究信息。
总共找到691项研究，其中14篇文章被纳入系统评价。含[某种成分]的细菌裂解物是研究最多的候选疫苗。作为人体对[某种疾病名称]免疫反应的主要指标，大多数研究测定了抗体反应。研究中的抗原量、免疫途径和免疫方案各不相同，是根据疾病模型、疫苗类型、接种环境（预防性或治疗性）等多种因素选择的。
大多数研究称其疫苗接种有效且安全，感染率降低以及诱导保护性抗体、细胞依赖性和/或细胞因子反应证明了这一点。总之，此处提供的信息将有助于研究人员更密切地研究[某种疾病名称]候选疫苗，并采取未来更有可能持续成功的行动。
